RT Journal Article SR Electronic T1 Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP e001931 DO 10.1136/jitc-2020-001931 VO 9 IS 1 A1 Aljosja Rogiers A1 Ines Pires da Silva A1 Chiara Tentori A1 Carlo Alberto Tondini A1 Joseph M Grimes A1 Megan H Trager A1 Sharon Nahm A1 Leyre Zubiri A1 Michael Manos A1 Peter Bowling A1 Arielle Elkrief A1 Neha Papneja A1 Maria Grazia Vitale A1 April A N Rose A1 Jessica S W Borgers A1 Severine Roy A1 Joanna Mangana A1 Thiago Pimentel Muniz A1 Tim Cooksley A1 Jeremy Lupu A1 Alon Vaisman A1 Samuel D Saibil A1 Marcus O Butler A1 Alexander M Menzies A1 Matteo S Carlino A1 Michael Erdmann A1 Carola Berking A1 Lisa Zimmer A1 Dirk Schadendorf A1 Laura Pala A1 Paola Queirolo A1 Christian Posch A1 Axel Hauschild A1 Reinhard Dummer A1 John Haanen A1 Christian U Blank A1 Caroline Robert A1 Ryan J Sullivan A1 Paolo Antonio Ascierto A1 Wilson H Miller Jr A1 F Stephen Hodi A1 Karijn P M Suijkerbuijk A1 Kerry L Reynolds A1 Osama E Rahma A1 Paul C Lorigan A1 Richard D Carvajal A1 Serigne Lo A1 Mario Mandala A1 Georgina V Long YR 2021 UL http://jitc.bmj.com/content/9/1/e001931.abstract AB Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer.Methods We analyzed data from 110 patients with laboratory-confirmed SARS-CoV-2 while on treatment with ICI without chemotherapy in 19 hospitals in North America, Europe and Australia. The primary objective was to describe the clinical course and to identify factors associated with hospital and intensive care (ICU) admission and mortality.Findings Thirty-five (32%) patients were admitted to hospital and 18 (16%) died. All patients who died had advanced cancer, and only four were admitted to ICU. COVID-19 was the primary cause of death in 8 (7%) patients. Factors independently associated with an increased risk for hospital admission were ECOG ≥2 (OR 39.25, 95% CI 4.17 to 369.2, p=0.0013), treatment with combination ICI (OR 5.68, 95% CI 1.58 to 20.36, p=0.0273) and presence of COVID-19 symptoms (OR 5.30, 95% CI 1.57 to 17.89, p=0.0073). Seventy-six (73%) patients interrupted ICI due to SARS-CoV-2 infection, 43 (57%) of whom had resumed at data cut-off.Interpretation COVID-19–related mortality in the ICI-treated population does not appear to be higher than previously published mortality rates for patients with cancer. Inpatient mortality of patients with cancer treated with ICI was high in comparison with previously reported rates for hospitalized patients with cancer and was due to COVID-19 in almost half of the cases. We identified factors associated with adverse outcomes in ICI-treated patients with COVID-19.All data relevant to the study are included in the article or uploaded as online supplemental information.